NeuBase Therapeutics Inc. [NASDAQ: NBSE] stock went on an upward path that rose over 106.96% on Wednesday, amounting to a one-week price increase of more than 217.33%. The company report on September 6, 2023 at 10:00 AM that SYMETRYX CORPORATION ACQUIRES 20% STOCK IN NEUBASE.
URGES BOARD TO CONSIDER A $1 DIVIDEND.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Today, Symetryx Corporation (“Symetryx”) announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc. (NASDAQ: NBSE) (“Neubase”). Symetryx is now urging the Board to issue a special $1 per share dividend.
Over the last 12 months, NBSE stock dropped by -80.81%. The average equity rating for NBSE stock is currently 3.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $5.83 million, with 1.69 million shares outstanding and 1.43 million shares in the current float. Compared to the average trading volume of 337.15K shares, NBSE stock reached a trading volume of 105498167 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on NeuBase Therapeutics Inc. [NBSE]:
H.C. Wainwright have made an estimate for NeuBase Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 12, 2021.
The Average True Range (ATR) for NeuBase Therapeutics Inc. is set at 0.32 The Price to Book ratio for the last quarter was 0.36, with the Price to Cash per share for the same quarter was set at 6.00.
NBSE Stock Performance Analysis:
NeuBase Therapeutics Inc. [NBSE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 217.33. With this latest performance, NBSE shares gained by 145.36% in over the last four-week period, additionally sinking by -42.54% over the last 6 months – not to mention a drop of -80.81% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBSE stock in for the last two-week period is set at 79.00, with the RSI for the last a single of trading hit 87.69, and the three-weeks RSI is set at 70.25 for NeuBase Therapeutics Inc. [NBSE]. The present Moving Average for the last 50 days of trading for this stock 1.3200, while it was recorded at 1.2400 for the last single week of trading, and 3.3900 for the last 200 days.
Insight into NeuBase Therapeutics Inc. Fundamentals:
Return on Total Capital for NBSE is now -74.21, given the latest momentum, and Return on Invested Capital for the company is -76.33. Return on Equity for this stock declined to -87.43, with Return on Assets sitting at -69.74. When it comes to the capital structure of this company, NeuBase Therapeutics Inc. [NBSE] has a Total Debt to Total Equity ratio set at 25.85. Additionally, NBSE Total Debt to Total Capital is recorded at 20.54, with Total Debt to Total Assets ending up at 18.34. Long-Term Debt to Equity for the company is recorded at 23.00, with the Long-Term Debt to Total Capital now at 18.28.
Reflecting on the efficiency of the workforce at the company, NeuBase Therapeutics Inc. [NBSE] managed to generate an average of -$912,877 per employee.NeuBase Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.50 and a Current Ratio set at 2.50.
NBSE Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NBSE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for NeuBase Therapeutics Inc. go to 4.00%.
NeuBase Therapeutics Inc. [NBSE] Institutonal Ownership Details
The top three institutional holders of NBSE stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in NBSE stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in NBSE stock with ownership which is approximately 5.7381%.
